Sigma Planning Corp Makes New Investment in Illumina, Inc. $ILMN

Key Points

• Sigma Planning Corp opened a new position in Illumina in Q4, acquiring 7,493 shares valued at about $983,000.
• Illumina beat quarterly estimates with $1.15 EPS and $1.09B revenue (+4.8% YoY) and set FY2026 EPS guidance of 5.150–5.300, roughly in line with analysts' forecasts (~5.15).
• The stock trades around $139 with a market cap of $21.17B, but analysts' consensus is a "Hold" with an average price target of $131.06, while institutional investors own about 89.4% of shares.

Sigma Planning Corp acquired a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 7,493 shares of the life sciences company's stock, valued at approximately $983,000.

Other institutional investors have also added to or reduced their stakes in the company. Creative Capital Management Investments LLC raised its holdings in Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock worth $26,000 after purchasing an additional 120 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the fourth quarter worth $26,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter worth $26,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the fourth quarter worth $26,000. Finally, Activest Wealth Management grew its stake in shares of Illumina by 671.9% in the fourth quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Trading Up 2.6%

Illumina stock opened at $139.37 on Tuesday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a one year low of $73.86 and a one year high of $155.53. The stock has a market capitalization of $21.17 billion, a PE ratio of 25.34, a price-to-earnings-growth ratio of 2.59 and a beta of 1.42. The business's fifty day moving average is $125.68 and its 200 day moving average is $126.90.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analysts' expectations of $1.07 billion. During the same period last year, the firm posted $0.97 earnings per share. Illumina's revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts predict that Illumina, Inc. will post 5.15 EPS for the current year.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company's stock, valued at $1,896,173.78. This trade represents a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

ILMN has been the topic of a number of recent research reports. Guggenheim increased their target price on Illumina from $144.00 to $170.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Wall Street Zen raised Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th. Stifel Nicolaus increased their target price on Illumina from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Tuesday, January 20th. Canaccord Genuity Group cut their target price on Illumina from $150.00 to $140.00 and set a "hold" rating on the stock in a research note on Friday. Finally, Piper Sandler cut their target price on Illumina from $195.00 to $170.00 and set an "overweight" rating on the stock in a research note on Monday, February 9th. Six analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Illumina has a consensus rating of "Hold" and an average price target of $131.06.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.